HELICOBACTER PYLORI INFECTIONS
Conditions
Keywords
Helicobacter pylori
Brief summary
Helicobacter pylori infection is a common global gastrointestinal infectious disease, affecting approximately 43.1% of the world's population. Eradicating H. pylori is crucial for reducing the risk of developing conditions such as gastritis, peptic ulcer disease, and gastric cancer. Currently, 14-day high-dose dual therapy containing amoxicillin and bismuth-containing quadruple therapy are the guideline-recommended first-line treatment regimens for H. pylori eradication. Treatment options for H. pylori vary considerably, with differing efficacy outcomes largely attributable to increasing bacterial antibiotic resistance. Furthermore, multiple factors influence the efficacy of H. pylori eradication, including smoking, body surface area, CYP2C19 gene polymorphisms, patient compliance, and regional variations. Therefore, to systematically evaluate the efficacy and safety of different treatment regimens alongside the cost-effectiveness of various therapeutic strategies, and to conduct ongoing critical analysis of clinical practice, this study proposes a long-term investigation of real-world clinical practice through a non-interventional cohort study registry. This will assess the effectiveness, safety, and temporal trends of different H. pylori infection treatment regimens, providing real-time evidence to support clinical practice.
Interventions
OTHERDoctors prescribe Helicobacter pylori treatment regimens for patients based on current guidelines and consensus statements, tailored to individual circumstance, not involve any intervention procedure.
Doctors prescribe Helicobacter pylori treatment regimens for patients based on current guidelines and consensus statements, tailored to individual circumstance, not involve any intervention procedure.
Sponsors
Yueyue Li
Qilu Hospital of Shandong University
Feicheng People's Hospital
Binzhou Maternal and Child Health Hospital
Jinxiang County People's Hospital
The People's Hospital of Jimo
Zibo Maternal and Child Health Hospital
Yantai Penglai Traditional Chinese Medicine Hospital
Zaozhuang Municipal Hospital
Linyi Yizhou Hospital
Taierzhuang District People's Hospital
Shandong University of Traditional Chinese Medicine
Yuncheng Traditional Chinese Medicine Hospital
Caoxian County Hospital
Qihe County People's Hospital
University Town Hospital, Afiliated Hospital of Shandong University of Traditional Chinese Medicine
Dezhou Hospital Qilu Hospital of Shandong University
The 2nd People's Hospital of Dongying City
Zhangdian District Hospital of Traditional Chinese Medicine
Yantai Zhifu Hospital
Inner Mongolia Autonomous Region International Mongolian Medicine Hospital
Hohhot Second Hospital
Guanxian People's Hospital
Longkou People's Hospital
Linshu County Hospital of Traditional Chinese Medicine
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* patients aged 18-80 years, regardless of gender; * willing to receive H. pylori eradication therapy; * diagnosed with H. pylori infection through at least one of the following methods: rapid urease test, ¹³C/¹⁴C-urea breath test, or histopathological examination.
Exclusion criteria
* patients with incomplete medical records, including missing treatment details, absence of post-treatment follow-up test results, or failure to complete essential follow-up assessments; * patients with severe underlying conditions such as hepatic insufficiency, renal insufficiency, or malignant tumours; * pregnant or breastfeeding women; * individuals who refuse to sign the informed consent form
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Eradication rate | at least 6 weeks after treatment completion |
Secondary
| Measure | Time frame |
|---|---|
| Adverse events | immediately after treatment completion |
Countries
China
Contacts
CONTACTYueyue Li
Outcome results
None listed